Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Utilizing TILs to stratify treatment strategies in breast cancer

Hope Rugo • 14 Mar 2025
BCC 2025
Breast Cancer

Hope Rugo, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, comments on the limitations of relying solely on tumor size for treatment decisions in early-stage breast cancer, highlighting the potential of tumor-infiltrating lymphocytes (TILs) as a prognostic factor. TILs have been shown to be highly prognostic in small node-negative tumors, and several trials are exploring the use of TILs to stratify treatment intensity, which can help tailor treatment to individual patients. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hope Rugo

Evaluating the role of chemotherapy in triple-negative breast cancer
2:41
Evaluating the role of chemotherapy in triple-negative breast cancer
Hope Rugo • 14 Mar 2025
Novel ADC and checkpoint inhibitor combinations in breast cancer
2:38
Novel ADC and checkpoint inhibitor combinations in breast cancer
Hope Rugo • 14 Mar 2025
What to look forward to in breast cancer at ASCO 2023
3:24
What to look forward to in breast cancer at ASCO 2023
Hope Rugo • 12 May 2023
Detailed safety analysis from the DESTINY-Breast04 trial
6:33
Detailed safety analysis from the DESTINY-Breast04 trial
Hope Rugo • 12 May 2023

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals